9/22/2023  9:25:55 PM Chg. -0.2000 Volume Bid9:59:57 PM Ask9:59:57 PM Market Capitalization Dividend Y. P/E Ratio
144.1000EUR -0.14% 62
Turnover: 8,955.7000
143.4000Bid Size: 80 143.6000Ask Size: 80 253.18 bill.EUR - -

Business description

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.
 

Management board & Supervisory board

CEO
Richard A. Gonzalez
Management board
Scott T. Reents, Carrie Strom, Dr. Azita Saleki-Gerhardt, Jeffrey R. Stewart, Perry C. Siatis, Rae L. Livingston, Robert A. Michael, Timothy J. Richmond, Kevin Buckbee, Nicholas Donoghoe, Tracie Haas, Thomas Hudson, Greg Miley, Elaine K. Sorg
Supervisory board
Richard A. Gonzalez, Brett J. Hart, Edward J. Rapp, Frederick H. Waddell, Glenn F. Tilton, Melody B. Meyer, Rebecca B. Roberts, Robert J. Alpern, Roxanne S. Austin, Thomas Freyman, William H.L. Burnside
 

Company data

Name: AbbVie Inc.
Address: 1 North Waukegan Road,North Chicago, Illinois 60064-6400, USA
Phone: +1-847-932-7900
Fax: -
E-mail: -
Internet: www.abbvie.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 96.70%
IPO date: 1/2/2013

Investor relations

Name: Liz Shea
IR phone: +1-847-935-2211
IR Fax: -
IR e-mail: liz.shea@abbvie.com

Main Shareholders

Others
 
64.91%
Vanguard Group Inc
 
9.03%
Blackrock Inc.
 
7.88%
State Street Corporation
 
4.43%
JP Morgan Chase & Company
 
3.22%
Capital International Investors
 
2.44%
Geode Capital Management, LLC
 
1.98%
Capital Research Global Investors
 
1.84%
Morgan Stanley
 
1.77%
Others
 
2.50%